Literature DB >> 24966616

Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitis.

Hao-Lan He1, Ji-Bin Zhang1, Qian Li1.   

Abstract

AIM: To investigate the clinical significance of expression of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in ulcerative colitis (UC).
METHODS: Thirty UC specimens taken by colonoscopy from patients with active UC treated at the Department of Pathology, Central Hospital Affiliated to Shenyang Medical College from February 2010 to January 2012 were included in an experimental group, and 30 normal colon tissue samples taken by colonoscopy from non-UC patients were included in a control group. Expression of TF and TFPI in UC and normal colon tissue samples was detected by immunohistochemistry.
RESULTS: The positive rate of TF in UC was significantly higher than that in normal colon tissue (63% vs 33%, χ(2) = 5.41, P < 0.05). The positive rate of TFPI in UC was also significantly higher than that in normal colon tissue (43% vs 17%, χ(2) = 5.08, P < 0.05).
CONCLUSION: Positive rates of TF and TFPI expression in UC are significantly higher than those in normal colon tissue. TF and TFPI may play an important role in the pathogenesis of UC.

Entities:  

Keywords:  Tissue factor; Tissue factor pathway inhibitor; Ulcerative colitis

Mesh:

Substances:

Year:  2014        PMID: 24966616      PMCID: PMC4064091          DOI: 10.3748/wjg.v20.i23.7461

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

Review 1.  Alternatively spliced tissue factor - one cut too many?

Authors:  Nigel Mackman
Journal:  Thromb Haemost       Date:  2007-01       Impact factor: 5.249

Review 2.  Tissue factor--a receptor involved in the control of cellular properties, including angiogenesis.

Authors:  J Chen; A Bierhaus; S Schiekofer; M Andrassy; B Chen; D M Stern; P P Nawroth
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

Review 3.  Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis.

Authors:  E Abraham
Journal:  Crit Care Med       Date:  2000-09       Impact factor: 7.598

4.  Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.

Authors:  P Enkhbaatar; K Okajima; K Murakami; M Uchiba; H Okabe; K Okabe; Y Yamaguchi
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

5.  Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease.

Authors:  J P Fägerstam; P A Whiss; M Ström; R G Andersson
Journal:  Inflamm Res       Date:  2000-09       Impact factor: 4.575

6.  Vascular endothelial growth factor (VEGF164) ameliorates intestinal epithelial injury in vitro in IEC-18 and Caco-2 monolayers via induction of TGF-beta release from epithelial cells.

Authors:  K Bulut; C Pennartz; P Felderbauer; N Ansorge; M Banasch; F Schmitz; W E Schmidt; P Hoffmann
Journal:  Scand J Gastroenterol       Date:  2006-06       Impact factor: 2.423

7.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis.

Authors:  M P Herman; G K Sukhova; W Kisiel; D Foster; M R Kehry; P Libby; U Schönbeck
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

8.  Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels.

Authors:  James T B Crawley; David A Goulding; Valérie Ferreira; Nicholas J Severs; Florea Lupu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-02-01       Impact factor: 8.311

9.  Two sites in the tissue factor extracellular domain mediate the recognition of the ligand factor VIIa.

Authors:  W Ruf; T S Edgington
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

10.  Platelets and anticoagulant capacity in patients with inflammatory bowel disease.

Authors:  Torben Bjerregaard Larsen; Jens Nederby Nielsen; Lisbeth Fredholm; Erik D Lund; Ivan Brandslund; Pia Munkholm; Henrik Hey
Journal:  Pathophysiol Haemost Thromb       Date:  2002 Mar-Apr
View more
  2 in total

1.  Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.

Authors:  Bilgehan Yüzbaşıoğlu; Müge Ustaoğlu; Şule Yüzbaşıoğlu; Ulaş Emre Akbulut; Kamil Özdil
Journal:  Turk J Gastroenterol       Date:  2019-12       Impact factor: 1.852

2.  Tissue factor in ulcerative colitis, with and without concomitant primary sclerosing cholangitis.

Authors:  Johan Vessby; Maria Lampinen; Mikael Åberg; Fredrik Rorsman; Agneta Siegbahn; Alkwin Wanders; Marie Carlson
Journal:  Ups J Med Sci       Date:  2019-11-27       Impact factor: 2.384

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.